Area of research
Obstetrics and Gynecology · Reproductive Medicine
Research interest
Research interests include Endometrial and Cervical Cancer Treatments, Ovarian cancer diagnosis and treatment, Cervical Cancer and HPV Research, and Inflammatory Biomarkers in Disease Prognosis.
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer − PORTEC-4a an international, randomised, phase 3 trial
Risk factors for recurrence of vulvar high-grade squamous intra-epithelial lesions: long-term follow-up of the PITVIN Study (primary imiquimod vs surgery for vulvar intra-epithelial neoplasia).
Torque teno virus is predictive for malignancies after kidney transplantation.
High CD36 expression in the tumor microenvironmental vasculature correlates with unfavorable overall survival in high grade serous ovarian cancer.
ctDNA as an Objective Marker for Postoperative Residual Disease in Primary Advanced High-Grade Serous Ovarian Cancer.
CT-based radiomic prognostic vector (RPV) predicts survival and stromal histology in high-grade serous ovarian cancer: an external validation study.
Surgical approach, preoperative LEEP/conization and patterns of recurrence and death in low-risk cervical cancer - exploratory analysis from the CCTG CX.5/SHAPE trial.
Best of ESMO 2024: gynecologic cancers
Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial.
Outcomes of low-risk endometrial cancer with isolated tumor cells in the sentinel lymph nodes: a prospective, multi-center, single-arm, observational study (ENDO-ITC study)
Novel Treatment Concepts for Cervical Cancer-Moving Towards Personalized Therapy.
Highlights from ASCO 2025—advances in the treatment of ovarian cancer
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
Prognostic role of transcription factor <i>ARID1A</i> in patients with endometrial cancer of no specific molecular profile (NSMP) subtype.
Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?
The Predictive Value of the Fibrinogen-Albumin-Ratio Index on Surgical Outcomes in Patients with Advanced High-Grade Serous Ovarian Cancer.
Oncologic and Obstetric Outcomes Following Radical Abdominal Trachelectomy in Non-Low-Risk Early-Stage Cervical Cancers: A 10-Year Austrian Single-Center Experience.
Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma.
Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres.
Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial
Influence of Clinical and Surgical Factors on Uterine Carcinosarcoma Survival.
Gestational and Non-gestational Trophoblastic Neoplasia. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 032/049, April 2022).
Krukenberg Progression of Gastric Carcinoma in Pregnancy: Is Early Diagnosis Possible? Case Report and Review of the Literature.
Real‐life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (<scp>RESPONSE</scp> trial)
Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).